SB202190

Catalog No.S1077 Batch:S107709

Print

Technical Data

Formula

C20H14N3OF
Molecular Weight 331.34 CAS No. 152121-30-7
Solubility (25°C)* In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 22 mg/mL (66.39 mM)
Water Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 8.000mg/ml (24.14mM) Taking the 1 mL working solution as an example, add 50 μL of 160 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with an IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. This compound inhibits endothelial cell Apoptosis via induction of Autophagy and heme oxygenase-1. It significantly suppresses Erastin‐dependent Ferroptosis.
Targets
Ferroptosis p38α
(Cell-free assay)		 p38β
(Cell-free assay)
50 nM 100 nM
In vitro

SB202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. This compound by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. Its Apoptosis related is attenuated by p38β but augmented by p38α. The chemical strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. Treatment with this inhibitor inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). It induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. This agent enhances the growth of THP-1 and MV4-11 cells. It increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by this compound.

In Vivo

Inhibiting p38 by administration of SB202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. In the endotoxin model of sepsis, treatment with this compound produces a statistically significant survival benefit compared with control.

Protocol (from reference)

Kinase Assay:

[1]
  • In vitro kinase assays

    The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Assay:

[2]
  • Cell Lines

    Jurkat, and HeLa

  • Concentrations

    Dissolved in DMSO, final concentrations ~50 μM

  • Incubation Time

    24 hours

  • Method

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.
Animal Study:

[5]
  • Animal Models

    C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG

  • Dosages

    12.5 μg

  • Administration

    Administered via i.d.

References

  • https://pubmed.ncbi.nlm.nih.gov/10998351/
  • https://pubmed.ncbi.nlm.nih.gov/9632706/
  • https://pubmed.ncbi.nlm.nih.gov/11439356/
  • https://pubmed.ncbi.nlm.nih.gov/16807361/
  • https://pubmed.ncbi.nlm.nih.gov/16908851/
  • https://pubmed.ncbi.nlm.nih.gov/18222647/
  • https://pubmed.ncbi.nlm.nih.gov/18995898/
  • https://pubmed.ncbi.nlm.nih.gov/19027920/
  • https://pubmed.ncbi.nlm.nih.gov/21159664/
  • https://pubmed.ncbi.nlm.nih.gov/22053010/
  • https://pubmed.ncbi.nlm.nih.gov/28887319/

Customer Product Validation

<p>We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.</p><div><div> </div></div><p> </p>

Data from [ J Biol Chem , 2010 , 285, 32824–32833 ]

<p>C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.</p><div><div> </div></div><p> </p>

Data from [ J Biol Chem , 2010 , 285, 32824–32833 ]

<p>C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).</p><div><div> </div></div><p> </p>

Data from [ J Biol Chem , 2010 , 285, 32824–32833 ]

Sellecks SB202190 Has Been Cited by 220 Publications

Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer [ Cancer Cell, 2025, S1535-6108(25)00271-5] PubMed: 40712568
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer [ Nat Cancer, 2025, 6(2):259-277] PubMed: 39820127
Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD [ Nat Metab, 2025, 7(10):2018-2032] PubMed: 40973819
Dual membrane receptor degradation via folate receptor targeting chimera [ Nat Commun, 2025, 16(1):8804] PubMed: 41038820
Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response [ J Exp Clin Cancer Res, 2025, 44(1):290] PubMed: 41094672
Aurantio-obtusin modulates Wilms Tumour 1 within the breast tumour microenvironment reducing immunosuppression and tumour growth [ Cell Commun Signal, 2025, 23(1):309] PubMed: 40598415
Comparison of characteristics and immune responses between paired human nasal and bronchial epithelial organoids [ Cell Biosci, 2025, 15(1):18] PubMed: 39920853
ERK1-mediated GLYCTK2 phosphorylation promotes fructolysis to sustain glioblastoma survival under glucose deprivation [ Cell Death Discov, 2025, 11(1):266] PubMed: 40467571
Single Low-Dose Ionizing Radiation Transiently Enhances Rat RIN-m5F Cell Function via the ROS/p38 MAPK Pathway Without Inducing Cell Damage [ Antioxidants (Basel), 2025, 14(2)120] PubMed: 40002307
Establishing Pancreatic Cancer Organoids from EUS-Guided Fine-Needle Biopsy Specimens [ Cancers (Basel), 2025, 17(4)692] PubMed: 40002285

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.